• Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=512

    BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract research, development, and manufacturing organizations) with major operations in China and the US. The combined company will operate as BioDuro-Sundia, providing fully integrated drug discovery, development, and manufacturing for both API (Active Pharmaceutical Ingredients) and drug products. Advent led a majority investment in Sundia, with Bridgewest Capital as co-investors. China eCapital Partners, LLC, the US affiliate of CEC Capital Group, served as Sundia’s financial advisor in this transaction.

  • Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=510

    CEC Capital Group participates as a lead investor On September 1, 2020, Thery Pharm (the “Company”), a benchmarking company for specialty Active Pharmaceutical Ingredients (APIs), announced the completion of a Series C financing round of nearly RMB 250 million. This financing round was jointly led by SND Ventures Group and CEC Capital Group. New investors include Golden Partners Capital, Suzhou Guofa Venture Capital, and Tahoe Venture. Existing shareholder Legend Capital also increased its holdings in the Company.

  • Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=531

    Following the announcement of the completion of its pre-Series C round of financing in July 2020, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO Technology” or the “Company”) officially announced the completion of over RMB 300 million in Series C financing. This round of financing was led by Loyal Valley Capital. Morningside Group, Shanghai Lingang Economic Development, Sherpa Healthcare Partners, Kunlun Investment, GP Hi-tech Capital, and BioTrack Capital participated as followers in the round. CEC Capital Group has served as the Company’s financial advisor in OBiO Technology’s pre-Series C and Series C rounds of financing, and has helped the Company complete more than RMB 600 million in equity financing within the past six months.

  • Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=527

    Fenlai Shangcheng (“Funlike” or the “Company”), a leading domestic supply chain service and social retail enablement platform in China, has recently completed its Series A financing of RMB 100 million. This round of financing was led by Cypress Capital (China) and Great Value Asset led the investment, with several followers participating in the round. With this round of financing, Funlike aims to accelerate the development and optimization of its brands, system tools, logistics and warehousing, after-sales services, marketing, and other capabilities. The Company also plans to expand its urban operation centers and deepen its upstream and downstream channel coverage, ultimately building a supply chain service platform centered on FMCGs.

  • Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=534

    XWPharma, formerly known as XW Laboratories (“XWPharma” or the “Company”), a research and development company focused on the development of innovative drugs for the treatment of central nervous system diseases, has recently announced the completion of its USD 40 million Series C financing round. This round of financing was led by Panacea Ventures. Other participants included CDIB Capital Group, Orient Hontai, and Trinity Innovation Fund. Existing investors Johnson & Johnson Development Corporation (JJDC), WI Harper Group, WuXi AppTec, and KTB Network also participated in the round. Proceeds from this round of financing will be used for the clinical development of two lead projects in the Company’s pipeline, XW10172 and XW10508. XW10172 is a GABAB receptor agonist used to treat sleep disorders caused by narcolepsy and neurodegenerative diseases (such as Parkinson’s disease). XW10508 is a clinical application based on glutamate NMDA receptor antagonism and AMPA receptor activation. The compound will be used to treat major depression and chronic pain diseases.

  • Cancel
    Date：2020-09

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=507

    Freenome, a portfolio company in CEC Capital Group’s Healthcare Fund, announced today that it has completed its Series C financing round of USD 270 million. The financing round was led by Bain Capital and Perceptive Advisors. Freenome was founded in 2015 and is headquartered in San Francisco. In 2017 and 2019, Freenome completed USD 65 million and USD 160 million in Series A and B financings, respectively. Freenome aims to develop simple and accurate blood testing methods to detect and screen early-stage cancers.

  • Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=526

    Suzhou Connect Biopharmaceuticals Co., Ltd. (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced the completion of its USD 115 million Series C financing led by RA Capital Management. New investors Lilly Asia Ventures, Boxer Capital, and HBM Healthcare Investments also joined the round along with existing investor Qiming Venture Partners. The Company also announced that, in conjunction with the financing, Derek DiRocco, Ph.D., Principal at RA Capital Management, is joining Connect Biopharma’s Board of Directors. The Company plans to use the proceeds of the Series C financing to support the ongoing Phase 2 clinical trial for CBP-201 in adult patients with moderate-to-severe atopic dermatitis (AD) and the ongoing Phase 2 trials of CBP-307 in patients with moderate-to-severe ulcerative colitis (UC). The Company also aims to expand the CBP-201 clinical development program into additional indications, and manufacture clinical material to support future Phase 3 trials of CBP-201 and CBP-307. The Company also expects to use a portion of the proceeds to advance additional preclinical programs into clinical development, including CBP-174, a small molecule in development for the treatment of pruritus.

  • Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=519

    Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.